FOS and colorectal carcinoma: EGF induction of DUSP5 and FOS were also strongly attenuated by a MEK inhibitor (trametinib), demonstrating that DUSP5 is a bone fide target of ERK signaling in KRAS/BRAF wild-type CRC cells (Fig. 2C).